COMPANY
Caspian Therapeutics, Inc.
“Caspian is pursuing a potentially disease-modifying approach aimed at restoring the body’s own insulin producing capacity through the selective expansion and improved function of the pancreatic β cells.” Source · checked Oct 13, 2026
Sourced facts
Therapeutic areas or services
- menin · caspiantherapeutics.com · checked Oct 13, 2026
- diabetes · caspiantherapeutics.com · checked Oct 13, 2026
- insulin · caspiantherapeutics.com · checked Oct 13, 2026
Focus / stage (company wording)
- diabetes · caspiantherapeutics.com · checked Oct 13, 2026
Headquarters address
- HQ: San Diego, CA · sec.gov · checked Oct 13, 2026
Funding (company or press release)
- Total Amount Sold $ 50,000,000 · sec.gov · checked Oct 13, 2026
Funding and NIH signals
- SEC Form D raise Raised $50M (Form D filed Sep 23, 2026). SEC Form D 0001231919-26-001219 (Sep 23, 2026)
Evidence (1 event)
- Sep 23, 2026 · SEC Form D 0001231919-26-001219
Name of Issuer: Caspian Therapeutics, Inc.; CIK: 2156247; Address: San Diego, CA; Submission type: D; Filing date: 2026-09-23; Industry Group: Biotechnology; Date of First Sale: 2026-09-08; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 50000000; Total Amount Sold: 50000000; Federal exemptions: 06b
- Sep 23, 2026 · SEC Form D 0001231919-26-001219